Genzyme to supply less than half of EU demand for Thyrogen
This article was originally published in Scrip
For the next several months, Genzyme will only be able to meet around 45% of the demand for its Thyrogen (thyrotropin alfa) in the EU, the company has warned the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP). The problem should be resolved by July when logistical issues connected with the transfer of manufacturing should be resolved.
You may also be interested in...
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.